Sheng Wang

Sheng Wang

Auto-generated profile, based on publicly available information

Sheng Wang

Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, PR China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2020 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
MLMengting Li
Mengting Li
HFHanyi Fang
Hanyi Fang
QLQingyao Liu
Qingyao Liu
YGYongkang Gai
Yongkang Gai
LYLujie Yuan
Lujie Yuan
XLXIAOLI LAN
XIAOLI LAN
Upconversion nanoparticles (UCNPs) have been widely employed for tumor imaging using magnetic resonance imaging (MRI) and upconversion luminescence (UCL) imaging. The short blood clearance time and immunogenicity of UCNPs have limited their further application in vivo. We have designed UCNPs camouflaged with an exterior red blood cell (RBC) membrane coating (RBC-UCNPs) to solve these problems. Moreover, because of some intrinsic disadvantages of MRI and UCL imaging, we investigated the use of pretargeted RBC-UCNPs for positron-emission tomography (PET) imaging to obtain more comprehensive information. Our data showed that RBC-UCNPs retained the immunity feature from the source cells and the superior optical and chemical features from the pristine UCNP cores. The tumor-targeting ability of RBC-UCNPs was enhanced by binding 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000] (DSPE-PEG-FA) molecules onto the cell membranes. PET imaging with short half-life radionuclides to visualize the RBC-UCNPs was successfully realized by a combination of pre-targeting and in vivo click chemistry. Blood chemistry, hematology, and histologic analysis suggested good in vivo biocompatibility of the RBC-UCNPs. Our method provides a new potential biomedical application of biomimetic nanoparticles.

22 February 2020 in Nano-Micro Letters
Verified
Journal Article
Open access
PDF file
HFHanyi Fang
Hanyi Fang
MLMengting Li
Mengting Li
QLQingyao Liu
Qingyao Liu
YGYongkang Gai
Yongkang Gai
LYLujie Yuan
Lujie Yuan
XLXIAOLI LAN
XIAOLI LAN
Highlights A biomimetic nanoprobe was built with cancer cell membrane-coated and Gd3+-doped upconversion nanoparticles. The nanoprobe could be applied to in vivo UCL/MRI/PET multimodality precise imaging and successfully differentiated MDA-MB-231 tumor models through in vivo tri-modality imaging, which may be used for breast cancer molecular classification.

1 June 2015 in Life Sciences
Verified
Journal Article
Closed access
ZMZhaowei Meng
Zhaowei Meng
JTJian Tan
Jian Tan
GZGuizhi Zhang
Guizhi Zhang
WTWeijun Tian
Weijun Tian
QFQiang Fu
Qiang Fu
AUArun Upadhyaya
Arun Upadhyaya

23 December 2019 in International Microbiology
Verified
Journal Article
Open access
PDF file
JKJindan Kai
Jindan Kai
SWSheng Wang
Sheng Wang
Antibiotic resistance is a growing global challenge to public health. Polymyxin is considered to be the last-resort antibiotic against most gram-negative bacteria. Recently, discoveries of a plasmid-mediated, transferable mobilized polymyxin resistance gene (mcr-1) in many countries have heralded the increased threat of the imminent emergence of pan-drug-resistant super bacteria. MCR-1 is an inner membrane protein that enables bacteria to develop resistance to polymyxin by transferring phosphoethanolamine to lipid A. However, the mechanism associated with polymyxin resistance has yet to be elucidated, and few drugs exist to address this issue. Here, we review our current understanding regarding MCR-1 and small molecule inhibitors to provide a detailed enzymatic mechanism of MCR-1 and the associated implications for drug design.

31 July 2023 in View
Verified
Journal Article
Open access
MLMengting Li
Mengting Li
SWSheng Wang
Sheng Wang
QKQunshou Kong
Qunshou Kong
XCXinyi Cheng
Xinyi Cheng
HYHuanhuan Yan
Huanhuan Yan
DJDawei Jiang
Dawei Jiang
In recent years, radiometals have been successfully applied to medicine because of their breadth of decay properties and increased production and availability. Bifunctional chelators play a key role in radiometal‐based radiopharmaceuticals, affecting the labeling, targeting, and pharmacokinetics of bioconjugations and ensuring the stable complexation of the metal in vivo. The capacity of macrocycles to form complexes with extremely high thermodynamics, kinetics, and stability compared to acyclic chelators continues to pique the curiosity of pharmacists and biochemists among all prospective chelators utilized for the radiometal chelation. As new imaging modalities and therapeutic targets develop, the discovery of novel ligand structures with suitable chemical and biological features encourages the modification of chelators with charge and chemical properties. Herein, we present a comprehensive review of developments of macrocyclic chelators for PET radiopharmaceuticals, including innovative chelating agents with new structures and known chelating agent modifications, and their physical‐chemical properties, as well as their biological characteristics and applications in vivo.

1 November 2014 in Life Sciences
Verified
Journal Article
Closed access
YZYujie Zhang
Yujie Zhang
ZMZhaowei Meng
Zhaowei Meng
MZMingfang Zhang
Mingfang Zhang
JTJian Tan
Jian Tan
WTWeijun Tian
Weijun Tian
XSXinghua Song
Xinghua Song